8-K: Skye Bioscience Reports Strong Nimacimab Phase 2a Extension Results

Skye Bioscience announced positive interim 52-week data from its Phase 2a extension study of nimacimab in combination with semaglutide, showing significant weight loss and reduced regain.

Summary

• 19 participants in the combination cohorts completed week 26 and were eligible for the extension study, maintaining their original treatment assignment (10 nimacimab plus semaglutide; 9 placebo plus semaglutide).
• Of the 10 participants in the nimacimab plus semaglutide arm who joined the extension study, 7 completed an additional 26 weeks of treatment, achieving a mean weight loss of 22.3% after 52 weeks, with no plateau observed.
• The combination therapy of nimacimab plus semaglutide remained safe and well-tolerated, with no serious adverse events (SAEs) or adverse events of special interest (AESIs) reported during the extension period.
• Of the 9 participants in the placebo plus semaglutide arm that joined the extension study, 7 completed an additional 26 weeks of treatment, resulting in a mean weight loss of 19.7% after 52 weeks.
• Participants treated with nimacimab plus semaglutide who entered a 13-week off-therapy follow-up period regained only 17.8% of their lost weight, representing over 50% mitigation of weight rebound compared to 37.3% for semaglutide alone.
• Nimacimab plus semaglutide increased fat loss by 37% and resulted in a significant additional decrease in waist circumference compared to semaglutide alone.

Sentiment

Score: 8

Explanation: StockSavvy.ai views this as a highly positive update, demonstrating strong efficacy and safety for nimacimab in combination with semaglutide, with promising durability and competitive weight loss outcomes.

Positives

• Achieved 22.3% mean weight loss at 52 weeks with nimacimab plus semaglutide, demonstrating strong efficacy.
• No weight loss plateau was observed at 52 weeks, suggesting potential for further efficacy with extended treatment.
• Demonstrated over 50% mitigation of weight rebound during the 13-week off-therapy follow-up (17.8% regain vs. 37.3% for semaglutide alone), indicating improved durability.
• Maintained a strong safety and tolerability profile over 52 weeks, with no serious adverse events or adverse events of special interest reported.
• Nimacimab appears to convert patients to 'Super Responders' when combined with semaglutide, enhancing weight loss outcomes.
• The combination therapy led to a 37% increase in fat loss and a significant decrease in waist circumference compared to semaglutide alone.
• The 52-week weight loss results are comparable to or better than other leading combination therapies in the obesity market.
• The company is evaluating higher doses of nimacimab, which preclinical data suggests could drive additional weight loss without safety concerns.
• Collaboration with Halozyme Therapeutics for ENHANZE technology aims to enable large volume dose administration, potentially improving patient preference and absorption.

Negatives

• The semaglutide-alone group in the extension study self-selected for 'Super Responders,' which made direct differentiation of the combination effect challenging in this specific subset.
• Current capital is projected to fund operations and key clinical milestones only into Q4 2026, explicitly excluding the anticipated clinical cost of a proposed Phase 2b study and associated manufacturing costs, indicating a future capital need.

Risks

• The initiation and design of any future clinical trials will be impacted by capital resources and the company's ability to obtain additional sources of capital.
• There is no guarantee that the potential for additional weight loss after 52 weeks will ultimately be observed.
• Higher dosing of nimacimab may not achieve increased efficacy and could potentially produce adversely different safety and tolerability results than those observed to date.
• Dependence on third parties in connection with product manufacturing, research, and preclinical and clinical testing.
• The company's ability to advance, obtain regulatory approval of, and ultimately commercialize nimacimab.
• Competitive products or approaches could limit the commercial value of nimacimab.
• Uncertainty regarding the timing and results of preclinical and clinical trials.
• The company's ability to fund development activities and achieve development goals.
• Potential impact of global pandemics, inflation, supply chain issues, government shutdowns, high interest rates, and adverse regulatory changes.
• The company's ability to protect its intellectual property.
• Risks associated with the company's common stock.

Future Outlook

Skye Bioscience expects full topline reporting of the CBeyond Phase 2a extension data, including nimacimab monotherapy data and 13-week off-therapy follow-up, in Q3 2026. The company plans to advance a Phase 2b program to rigorously reproduce the combination effect at scale, optimize dose and regimen, and evaluate higher doses of nimacimab, with a goal of positioning nimacimab as a differentiated long-term option for obesity and related metabolic diseases. Current capital is projected to fund operations and key clinical milestones into Q4 2026, but this excludes the anticipated clinical cost of a proposed Phase 2b study and associated manufacturing costs.

Management Comments

• "Compared to other combination treatments, we believe 22.3% weight loss with no observed plateau at 52 weeks is clinically meaningful and commercially competitive, and is comparable to other combinations that have been evaluated." Puneet Arora, MD, FACE, Chief Medical Officer.
• "These results suggest that we could see even more weight loss with treatment beyond 52 weeks. We also expect even deeper weight loss with more optimized dosing of nimacimab in potential future clinical trials." Puneet Arora, MD, FACE, Chief Medical Officer.
• "Today's interim data reinforces our vision to build a leading platform that is distinct yet complementary and able to intensify incretin outcomes and help patients achieve more durable metabolic benefit." Punit Dhillon, Chief Executive Officer.
• "We believe nimacimab's attributes complement GLP-1 therapy through peripheral CB1 inhibition, with the potential to deepen weight loss and mitigate rebound during treatment interruptions." Punit Dhillon, Chief Executive Officer.
• "Our focus now is characterizing peripheral drug exposure at higher doses, dose selection, and developing plans to advance a Phase 2b program to rigorously reproduce the combination effect at scale, and optimize dose and regimen, with a goal of positioning nimacimab as a potential differentiated long-term option in obesity and related metabolic diseases." Punit Dhillon, Chief Executive Officer.

Industry Context

StockSavvy.ai notes that Skye Bioscience is strategically positioning nimacimab as a complementary, rather than competitive, therapy to existing incretin-based drugs like semaglutide (Wegovy). The reported 22.3% weight loss at 52 weeks with the combination therapy is presented as clinically meaningful and commercially competitive, aligning with the industry's demand for more effective and durable weight loss solutions. The emphasis on mitigating weight regain and avoiding neuropsychiatric side effects differentiates nimacimab from earlier CB1 inhibitors and positions it favorably in a rapidly evolving obesity treatment market currently dominated by GLP-1 agonists.

Comparison to Industry Standards

• Nimacimab 200mg + Semaglutide achieved 22.3% weight loss at 52 weeks, with no plateau observed, which is a strong result.
• This compares favorably to Wegovy, which showed -16.9% weight loss in the STEP-1 trial.
• The 22.3% weight loss is comparable to or slightly below Zepbound (-22.5% at 72 weeks in SURMOUNT-1) and Retatrutide (-24.2% at 48 weeks in Phase 2).
• It is also comparable to other combination therapies such as Eloralinatide (9mg, -20.1%), CT-388 (-22.5%), CagriSema (-22.7% PP at 68 weeks), MariTide (-20.0%), Survodutide (-18.7%), and Bimagrumab (30mg/kg) + Semaglutide (-22.0%).
• The combination's ability to significantly reduce weight regain (17.8% vs. 37.3% for semaglutide alone) offers a potential durability advantage over semaglutide monotherapy, which typically sees substantial rebound upon discontinuation.

Stakeholder Impact

• Shareholders: Positive clinical data could increase investor confidence and potentially lead to share price appreciation. However, the explicit need for future capital for Phase 2b introduces potential dilution risk.
• Patients: Offers a promising new therapeutic option for obesity, particularly for those seeking greater weight loss, reduced weight regain, or an alternative/additive to existing GLP-1 therapies without additional gastrointestinal burden or neuropsychiatric side effects.
• Healthcare Providers: Provides a potential new tool for managing obesity, especially for patients who have plateaued on GLP-1s or require more significant weight reduction.
• Competitors: Nimacimab's differentiated mechanism and strong results could pose a competitive challenge in the rapidly evolving obesity treatment market.

Next Steps

• Full topline reporting of the CBeyond Phase 2a extension data, including nimacimab monotherapy data and 13-week off-therapy follow-up, is expected in Q3 2026.
• Evaluating potential further extensions of the Phase 2a study to evaluate higher doses of nimacimab.
• Advancing a Phase 2b program to rigorously reproduce the combination effect at scale, optimize dose and regimen, and evaluate higher doses of nimacimab.
• Initial manufacturing runs needed to enable a subsequent trial and planning activities.
• Conducting a Phase 2b adaptive design dose-ranging study to optimize combination therapy doses and define individual contributions of nimacimab and semaglutide.
• Potential future pipeline expansion with additional combination opportunities, such as with tirzepatide.

Key Dates

Recommendation

The interim 52-week data for nimacimab in combination with semaglutide demonstrates highly compelling efficacy, achieving 22.3% weight loss with no plateau and significantly reducing weight regain. This profile is competitive with leading obesity treatments and suggests a differentiated mechanism that complements GLP-1s without adding tolerability burden. While future capital is needed for Phase 2b, the strong clinical proof-of-concept significantly de-risks the asset and positions Skye Bioscience for substantial growth in the large and expanding obesity market.

Keywords

Skye Bioscience, nimacimab, obesity, weight loss, semaglutide, Phase 2a extension study, CB1 inhibitor, metabolic health, clinical trial, biotechnology, drug development, CBeyond, GLP-1, pharmacology, biopharma